1. Stagnitti MN. Trends in antipsychotics purchases and expenses for the U.S. civilian noninstitutionalized population, 1997 and 2007. Statistical Brief #275. Agency for Healthcare Research and Quality, Rockville, MD. 2010.
2. Ahrnsbra R, Stagnitti MN. Comparision of antidepressant and antipsychotic utilization and expenditures in the U.S. civilian noninstitutionalized population, 2013 and 2018. Statistical Brief #534. Agency for Healthcare Research and Quality, Rockville, MD. 2021.
3. Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res. 2012;138:18–28.
4. Dilks S, Xavier RM, Kelly C, Johnson J. Implications of antipsychotic use: antipsychotic-induced movement disorders, with a focus on tardive dyskinesia. Nurs Clin N Am. 2019;54:595–608.
5. Muhlbauer V, Mohler R, Dichter MN, Zuidema SU, Kopke S, Luijendijk HJ. Antipsychotics for agitation and psychosis in people with Alzheimer’s disease and vascular dementia. Cochrane Database Syst Rev. 2021;12:CD013304.